Tag: #fda

Articles related to fda

health

FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival

FDA approves Lembaz (adrabetadex) for infantile-onset Niemann-Pick type C — the first therapy shown to extend survival in this ultra-rare childhood disorder.

#fda, #rare-disease, #npc, #drug-approval

health

FDA Approves Sunharbo, First Factor XIa Inhibitor, to Reduce Recurrent Ischemic Stroke in High‑Risk Adults

FDA approved Sunharbo (asundexian), the first U.S. factor XIa inhibitor, to prevent recurrent ischemic stroke in certain high‑risk adults alongside antiplatelet therapy.

#stroke, #asundexian, #fda, #bayer, #fxia

health

FDA Grants Accelerated Approval to Rybrevant Faspro for Recurrent, Metastatic Head and Neck Cancer

FDA grants accelerated approval to Janssen's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma after chemo and immunotherapy.

#oncology, #fda, #drugapproval, #headandneck, #janssen

health

FDA Expands Approval of Talzenna Plus Xtandi for HRR‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

FDA on Oct. 26 approved Talzenna plus Xtandi for HRR‑mutated metastatic castration‑sensitive prostate cancer; genetic testing required.

$PFE, #fda, #prostatecancer, #oncology, #pfizer

health

FDA Approves Hibsago, First Antisense Therapy for Chronic Hepatitis B, for Select Adults

FDA approves Hibsago (bepirovirsen), the first antisense drug for chronic hepatitis B, offering some adults a monitored path off long-term antivirals.

$GSK, #hepatitis_b, #fda, #gsk, #bepirovirsen

health

FDA Grants Accelerated Approval for GSK’s Jemperli in Biomarker-Defined Locally Advanced Rectal Cancer

FDA grants accelerated approval to GSK’s Jemperli for adults with stage II–III dMMR/MSI‑H locally advanced rectal cancer, potentially avoiding surgery.

$GSK, #health, #cancer, #fda, #immunotherapy

health

FDA Expands Use of Anktiva to Treat High-Grade Papillary Non‑Muscle Invasive Bladder Cancer

FDA expands Anktiva's approved use to adults with BCG‑unresponsive, high‑grade papillary-only non‑muscle invasive bladder cancer, providing a bladder‑sparing option.

#fda, #bladdercancer, #immunotherapy, #immunitybio

health

FDA OKs Pfizer’s TUKYSA for Front‑line Maintenance in HER2‑Positive Metastatic Breast Cancer

FDA expands Pfizer's TUKYSA for front‑line maintenance in unresectable/metastatic HER2‑positive breast cancer; PFS improved 8.6 months, liver risks noted.

$PFE, #her2, #breastcancer, #pfizer, #fda

health

Garetosmab (Pasatru) sharply reduces new bone lesions in adults with FOP, phase 3 Lancet trial shows; FDA approved Aug. 19, 2026

Phase 3 Lancet trial shows garetosmab cuts new heterotopic bone lesions by ~90% in adults with FOP; FDA approved Pasatru Aug. 19, 2026.

#fop, #garetosmab, #raredisease, #fda

health

FDA Approves Zanvastro, First Therapy for Alexander Disease

FDA approves Zanvastro (zilganersen), the first approved therapy for Alexander disease, for patients from infancy through adulthood. Ionis received approval.

$IONS, #health, #fda, #alexanderdisease, #ionis

health

FDA Clears Abbott’s Libre Duo 10 Day, First U.S. Wearable to Continuously Monitor Ketones and Glucose

FDA authorizes Abbott’s Libre Duo 10 Day, the first U.S. wearable to continuously monitor ketones and glucose for ages 2 and up.

#diabetes, #fda, #medicaldevices, #abbott

health

FDA approves Moderna’s first seasonal mRNA flu vaccine — full approval for 50–64, accelerated OK for 65+

FDA approved Moderna’s mRNA-1010 seasonal flu vaccine (mFLUSIVA), giving full approval for ages 50–64 and accelerated approval for 65+, pending a confirmatory study.

$MRNA, #moderna, #influenza, #fda, #vaccines

health

FDA Grants Accelerated Approval to Replimune’s Tudriqev for PD-1–Resistant Advanced Melanoma

FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.

$RPLM, #melanoma, #fda, #oncology, #replimune, #drugapproval

health

Deramiocel improves arm function and cardiac measures in phase 3 trial as FDA advisory panel reviews Capricor's application

Phase 3 trial of deramiocel (CAP-1002) showed significant benefits on upper-limb function and cardiac measures; FDA advisory panel is reviewing the data.

$CAPR, #duchenne, #muscular-dystrophy, #biotech, #fda

health

FDA expands Casgevy gene therapy to children as young as 2 for sickle cell and beta-thalassemia

FDA clears Vertex’s Casgevy for children aged 2+ with sickle cell disease or transfusion-dependent beta-thalassemia, widening access to a one-time gene therapy.

$VRTX, #sicklecell, #gene-therapy, #casgevy, #vertex, #fda